Home / Health / Amgen's MariTide Maintains Weight Loss, Improves Diabetes
Amgen's MariTide Maintains Weight Loss, Improves Diabetes
13 Jan
Summary
- MariTide demonstrated sustained weight loss in patients in a second study.
- The drug also significantly reduced blood sugar in Type 2 diabetes patients.
- Amgen's MariTide offers less frequent dosing compared to current market leaders.
Amgen's experimental obesity drug, MariTide, has demonstrated significant potential in recent clinical studies. An extended trial indicated that patients successfully maintained substantial weight loss achieved in earlier phases. This suggests MariTide could offer a valuable option for long-term weight management.
The drug also showed promise in a separate mid-stage trial involving patients with Type 2 diabetes. Results from this study revealed that MariTide led to clinically meaningful reductions in both blood sugar levels, measured by HbA1c, and overall body weight.
Amgen emphasized MariTide's distinct advantage in dosing frequency, positioning it as a potential competitor to current weekly injection weight-loss medications. The company is actively pursuing further development through Phase 3 trials to confirm these promising findings.
